The Novel Anti-Cancer Agent, SpiD3, Is Cytotoxic in CLL Cells Resistant to Ibrutinib or Venetoclax

Background: B-cell receptor (BCR) signaling is a central driver in chronic lymphocytic leukemia (CLL), along with the activation of pro-survival pathways (e.g., NF-κB) and aberrant anti-apoptotic mechanisms (e.g., BCL2) culminating to CLL cell survival and drug resistance. Front-line targeted therap...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Hemato
المؤلفون الرئيسيون:	Alexandria P. Eiken, Elizabeth Schmitz, Erin M. Drengler, Audrey L. Smith, Sydney A. Skupa, Kabhilan Mohan, Sandeep Rana, Sarbjit Singh, Jayapal Reddy Mallareddy, Grinu Mathew, Amarnath Natarajan, Dalia El-Gamal
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	MDPI AG 2024-08-01
الموضوعات:	chronic lymphocytic leukemia (CLL) drug resistance SpiD3 ibrutinib venetoclax unfolded protein response (UPR)
الوصول للمادة أونلاين:	https://www.mdpi.com/2673-6357/5/3/24